| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 435600170 | Involving a nucleic acid encoding a receptor, cytokine, hormone, growth factor, ion channel protein, or membrane transporter protein | 25 |
| 20110129845 | METHOD OF DIAGNOSIS - The present invention relates generally to a method of diagnosing, predicting and/or monitoring the development or progress of an airway tissue inflammatory response in a mammal. More particularly, the present invention relates to a method of diagnosing, predicting and/or monitoring the development or progress of an airway tissue inflammatory response by analysis of activin and/or follistatin levels in the breath condensate of said mammal. The present invention further provides a method for predicting, diagnosing and/or monitoring conditions associated with or characterised by the onset of an airway tissue inflammatory response. Also provided are diagnostic agents useful for detecting activin expression levels. | 06-02-2011 |
| 20110151473 | Polynucleotides and Polypeptides Encoding Receptors - Receptor polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing receptor polypeptides and polynucleotides in the design of protocols for the treatment of diseases and diagnostic assays for such conditions. | 06-23-2011 |
| 20110159513 | METHODS AND SYSTEMS FOR PREDICTING RESPONSE OF CELLS TO A THERAPEUTIC AGENT - The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided. | 06-30-2011 |
| 20110165584 | Variable Lymphocyte Receptors, Related Polypeptides and Nucleic Acids and Uses Thereof - Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). | 07-07-2011 |
| 20110171660 | USE OF CCR9, CCL25/TECK, AND INTEGRIN ALPHA4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE - The invention relates to methods for determining whether a melanoma will metastasize or has metastasized to the small intestine in a subject by detecting or quantifying the expression of the CCR9, CCL25/TECK, or integrin α4 gene. Also disclosed are methods for treating subjects so identified. | 07-14-2011 |
| 20110195426 | NUCLEIC ACIDS ANALYSIS - The present invention is partly based on the discovery that adverse factors can prevent an effective extraction of nucleic acids from a biological sample and that novel and unexpected agents and steps may be used to mitigate or remove the adverse factors, thereby dramatically improving the quality of the extracted nucleic acids. As such, one aspect of this invention is a novel method for extracting high quality nucleic acids from a biological sample. The high quality extractions obtained by the novel methods described herein are characterized by high yield and high integrity, making the extracted nucleic acids useful for various applications in which high quality nucleic acid extractions are preferred, e.g., a diagnosis, prognosis or therapy evaluation for a medical condition. | 08-11-2011 |
| 20110195427 | SYSTEMS AND METHODS FOR DETECTING PREGNANCY - Systems and methods for detecting pregnancy. In at least one embodiment of a system of the present disclosure, the system comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for pregnancy in a body fluid comprising the diagnostic marker, and a detection agent capable of detecting the diagnostic agent. | 08-11-2011 |
| 20110250609 | Methods For The Detection, Analysis And Isolation Of Nascent Proteins - This invention relates to non-radioactive markers that facilitate the detection and analysis of nascent proteins translated within cellular or cell-free translation systems. Nascent proteins containing these markers can be rapidly and efficiently detected, isolated and analyzed without the handling and disposal problems associated with radioactive reagents. Preferred markers are dipyrrometheneboron difluoride (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) dyes. | 10-13-2011 |
| 20110262928 | DISEASE MARKERS AND USES THEREOF - The present invention encompasses miRNA profiles and type-I IFN/IFNα-induced PD marker profiles in inflammatory or autoimmune disorders, such as myositis. The profiles may also be used in, for example, methods of treating patients, methods of monitoring disease progression of patients, and in diagnosing or providing a prognosis to patients having inflammatory or autoimmune disorders. | 10-27-2011 |
| 20110269144 | RYANODINE RECEPTOR POLYPEPTIDES - The genes encoding ryanodine receptor homologs have been characterized from multiple insect families including lepidopteran tobacco budworm ( | 11-03-2011 |
| 20110269145 | Cancer Risk Biomarkers - The present invention relates to methods and compositions for identifying biomarkers that indicate a biological state, in particular cancer or predisposition to cancer. | 11-03-2011 |
| 20120040367 | CONSTRUCT SYSTEM AND USES THEREFOR - The present invention discloses construct systems and methods for comparing different iso-accepting codons according to their preference for translating RNA transcripts into proteins in cell or tissues of interest or for producing a selected phenotype in an organism of interest or part thereof. The codon preference comparisons thus obtained are particularly useful for modifying the translational efficiency of protein-encoding polynucleotides in cells or tissues of interest or for modulating the quality of a selected phenotype conferred by a phenotype-associated polypeptide upon an organism of interest or part thereof. | 02-16-2012 |
| 20120142015 | GFP FUSION PROTEINS AND THEIR USE - The present invention provides fusion proteins including a green fluorescent protein inserted into the internal amino acid sequence of a Gαs protein and further provides method of using the fusion protein construct to follow activation of a G-protein receptor by a candidate drug. | 06-07-2012 |
| 20120237942 | METHODS AFFECTING MARKERS IN PATIENTS HAVING VASCULAR DISEASE - Marker levels and forms can be modulated in patients having vascular disease when sufficient vascular tissue is removed. The markers can be, e.g., from tissue, blood or lymph. The markers are typically involved in molecular pathways which are in turn modulated. Atherectomy catheters are used for accomplishing sufficient removal of vascular tissue to effect the modulations. | 09-20-2012 |
| 20130065244 | METHOD FOR PRODUCING cAMP USING CHIMERIC OLFACTORY RECEPTOR - A method for producing cAMP using a chimeric olfactory receptor. The method includes a step of preparing a reaction system comprising a first layer, a lipid bilayer membrane, and a second layer, and a step of supplying a chemical substance which stimulates the chimeric olfactory receptor to the first layer so as to produce the cAMP from ATP. The lipid bilayer membrane includes the chimeric olfactory receptor and adenylate cyclase. The chimeric olfactory receptor penetrates the lipid bilayer membrane. The second layer contains ATP and a G protein. The G protein is placed in the vicinity of one end of the chimeric olfactory receptor. The chimeric olfactory receptor is derived from a mouse olfactory receptor and the N-terminal of the chimeric olfactory receptor is modified with an amino acid sequence. | 03-14-2013 |
| 20130224756 | OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL - The invention provides methods, cells and constructs for optical measurement of membrane potential. These methods can be used in cells that are not accessible to presently available methods using electrodes. The methods can be directed to, for example, high-throughput drug screening assays to determine agents that can affect membrane potential of a target cell. | 08-29-2013 |
| 20130273553 | STABILIZATION OF CYCLIC PEPTIDE STRUCTURES - In various aspects, the invention provides methods for cyclizing proteins, including methods for enhancing the stability of cyclized proteins under cytosolic conditions. The invention also provides various methods for using the cyclized proteins. For example, cyclized proteins of the invention may be used in screening assays analogous to the yeast two hybrid assay. Selected embodiments of the invention provide cyclized single chain variable fragment (ScFv) molecules, including molecules in the form of an immunoglobulin fold. | 10-17-2013 |
| 20130302816 | NUCLEAR DNA CONTENT OF CHO CELL LINES AS A SELECTION CRITERION IN SCREENING OF THE BEST RECOMBINANT PROTEIN PRODUCERS - The present invention relates to a method for selecting for cells or cell lines that produce a recombinant protein/polypeptide in high yields, the method allowing for the selection of high producer cells or cell lines in an early phase of cell line development, the method comprising the step of determining the nuclear DNA content of the cells or cell lines, wherein the level of the nuclear DNA content of the cells or cell lines positively correlates with the capacity of the cells or cell lines to produce the recombinant protein/polypeptide. | 11-14-2013 |
| 20140017695 | ISOLATING CELLS EXPRESSING SECRETED PROTEINS - A method of detecting and isolating cells that produce a secreted protein of interest (POI) that has a T cell receptor variable domain, comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule. | 01-16-2014 |
| 20140072979 | ISOLATING CELLS EXPRESSING SECRETED PROTEINS - A method of detecting and isolating cells that produce a secreted protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain, comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule. | 03-13-2014 |
| 20140072980 | ISOLATING CELLS EXPRESSING SECRETED PROTEINS - A method of detecting and isolating cells that produce a secreted protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain, comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule. | 03-13-2014 |
| 20140178892 | SCREENING METHODS BASED ON VESICLE MOBILITY - The invention relates to a method of screening for a compound useful in the treatment of a disease selected from neurodegenerative diseases and neuro-inflammatory diseases, said method comprising providing a test cell; staining at least one organelle of said test cell; contacting said test cell with a test compound; and recording the path of said stained organelle in said test cell. Suitable compounds are identified from a comparison of the recorded path with a suitable reference. | 06-26-2014 |
| 20140206012 | Method for Identifying Agents that Inhibit Cell Migration, Promote Cell Adhesion and Prevent Metastasis - Disclosed are methods for identification of agents that modulate cell attachment, cell migration and cell viability. Cancer and primary cells adhered to a matrix are treated with agent(s) that modulate ActRII signaling and cell adhesion. Agents are tested that modulate cell adhesion, detachment, invasion and viability. Agents that modulate the expression, phosphorylation, function and translocation of ActRII signaling pathway members also can predict agents that modulate cell adhesion, detachment, invasion and viability. The methods have utility in tissue engineering as well as identifying agents that prevent cancer cell metastasis, wound dehiscence, aortic dissection and aid retina attachment and skin replacement and fertility. Examples of tissue engineering include techniques that allow for the generation of biological substitutes that restore, maintain, or improve tissue function or a whole organ. | 07-24-2014 |
| 20140212887 | SCREENING METHOD FOR THERAPEUTIC AGENT FOR CHONDROPATHY AND MODIFIED CHONDROCYTE FOR TREATMENT OF CHONDROPATHY - The use of salt-inducible kinase 3 allows screening for a substance having an effect of increasing cartilage volume and/or an effect of normalizing chondrocyte differentiation. A modified chondrocyte in which the expression or function of salt-inducible kinase 3 gene is inhibited or enhanced can be used to ameliorate a disease associated with reduced cartilage volume and/or a disease associated with impaired cartilage growth. | 07-31-2014 |
| 20140287425 | GLUCOSE AND INSULIN SENORS AND METHODS OF USE THEREOF - Described herein are glucose and insulin sensors. The sensors are composed of host cells with DNA specifically designed to produce fluorescence when the cells come into contact with glucose and/or insulin in the sample. Once the fluorescence has been quantified, it can be correlated with the amount of glucose and/or insulin present in the sample. | 09-25-2014 |
